Envista declares the sale of its KaVo processing models and devices enterprise to Planmeca

BREA, California., September 7, 2021 / PRNewswire / – Envista Holdings Company (NYSE: NVST) (“Envista”) at the moment introduced that it has entered right into a binding settlement for the sale of its KaVo processing models and devices enterprise to planmeca Verwaltungs GmbH (” Planmeca “) for an quantity of as much as $ 455 million, which features a potential extra cost of as much as $ 30 million. The sale must be finalized on the finish of 2021. The turnover of the divested exercise quantities to roughly $ 357 million and $ 317 million throughout fiscal years 2019 and 2020, respectively.

KaVo Remedy Unit & Devices is among the world’s main builders, producers and suppliers of dental therapy models and devices, with a world-renowned model recognized for its 100-year historical past of innovation, design of superior and prime quality manufacturing of dental tools. Based in 1909, KaVo is headquartered in Biberach, Germany, is current in additional than 60 nations and employs round 1,500 folks.

CEO of Envista Holdings Company Amir Aghdaei mentioned, “Envista is specializing in its strategic priorities to create and optimize a portfolio that’s extra consumables and digital centered and centered on workflows. This sale will higher place Envista to speculate organically and inorganically and increase our product providing in these areas. “

The enterprise on the market is a part of the Tools and Consumables phase of Envista. Envista’s Imaging enterprise, which additionally at present makes use of the KaVo model for sure merchandise, will stay with Envista as a part of the Tools and Consumables phase.

It’s anticipated that the KaVo processing models and devices enterprise will likely be reported as a discontinued operation as of Envista’s 10-Q submitting within the third quarter of 2021.

The transaction is topic to the satisfaction of sure customary closing situations, together with acquiring relevant regulatory approvals. The transaction just isn’t topic to financing situations or to a shareholder vote.

JP Morgan Securities LLC acted as monetary advisor and Kirkland & Ellis LLP acted as authorized advisor to Envista in reference to the transaction.

Additional particulars of the transaction will likely be offered in a present report on Kind 8-Okay which will likely be filed by Envista and accessible at www.sec.gov.


Envista is a worldwide household of greater than 30 trusted dental manufacturers, together with KaVo, Kerr, Nobel Biocare and Ormco, united by a standard purpose: partnering with professionals to enhance lives. Envista helps its clients present the absolute best affected person care by means of cutting-edge dental consumables, options, applied sciences and providers. Our complete portfolio, comprising dental implants and therapy choices, orthodontics and digital imaging applied sciences, covers roughly 90% of dentists’ medical wants for the analysis, therapy and prevention of dental situations in addition to the enhancing the aesthetics of the human smile. With a basis made up of the confirmed Envista Enterprise System (EBS) methodology, an skilled administration workforce and a robust tradition based mostly on steady enchancment, dedication to innovation and a deep buyer focus, Envista is properly outfitted to satisfy end-to-end wants. wants of dental professionals all over the world. Envista is among the world’s largest dental product corporations, with important market positions in among the most engaging segments of the dental product business. For extra data, please go to www.envistaco.com.


Sure statements contained on this press launch are “forward-looking” statements inside the that means of federal securities legal guidelines. There are a selection of essential elements which might trigger precise outcomes, developments and enterprise selections to vary materially from these advised or indicated by these forward-looking statements, and you shouldn’t place undue reliance on such forward-looking statements. These elements embody, amongst others, the impact of the announcement of the transaction on the Firm’s enterprise relationships, working outcomes, the share value or the enterprise normally, the incidence of any occasion or different circumstances which might give rise to the termination of the acquisition contract, the end result of any authorized proceedings which could possibly be initiated in opposition to the Firm associated to the transaction, the non-compliance with one of many situations of realization of the transaction and the failure to understand the anticipated advantages ensuing from the transaction, the influence of the COVID-19 pandemic, together with new variants of the virus, the tempo of restoration of the markets during which we function, the situations of the US and international financial system, the markets we serve and the monetary markets, the influence of our debt obligations on our operations and liquidity, developments and uncertainties in commerce insurance policies and laws, co Intractions or progress charges and cyclicality of the markets we serve, fluctuations within the stock of our distributors and clients, the lack of a key distributor, {our relationships} with and the efficiency of our distribution companions, competitors, our capability to efficiently develop and market new services and products, the potential for inappropriate conduct by our staff, brokers or enterprise companions, our compliance with relevant legal guidelines and laws (together with laws referring to medical gadgets and the healthcare business, well being), the outcomes of our medical trials and their perceptions, the penalties related to any non-Advertising Authorization of our merchandise, the modifications made to our merchandise which require new authorizations or advertising authorizations, our capacity to successfully handle price reductions and different adjustments within the healthcare business, our capacity to establish and efficiently full the suitable strategic acquisitions and investments, our capacity to combine the companies we purchase and obtain the anticipated advantages of such acquisitions, situation of the capabilities referring to acquisitions, investments and divestitures, important restrictions and / or potential legal responsibility based mostly on the tax implications of transactions with Danaher, breaches of safety or different disruptions to our laptop methods or breaches of information privateness legal guidelines, our capacity to adequately defend our mental property, the influence of our enterprise of restructuring on our progress capability, alternate price dangers, adjustments in tax legal guidelines relevant to multinational corporations, litigation and different contingent liabilities, together with mental property and environmental, well being and issues of safety, the dangers related to ow merchandise, service or software program defects, dangers in product manufacturing, commodity prices and dietary supplements, our capacity to regulate buying and manufacturing capability to replicate market situations, reliance on distinctive or restricted sources of provide, the influence of laws on demand for our services and products, labor points, worldwide financial, political, authorized, compliance and commerce elements, and war-related disruptions, terrorism, widespread protests and civil unrest, pure and man-made disasters, public well being issues and different occasions. Further data concerning elements that would trigger precise outcomes to vary materially from these forward-looking statements will be present in our filings with the SEC, together with our annual report on Kind 10-Okay for fiscal 2020 and our quarterly reviews on kind. 10-Q. These forward-looking statements converse solely as of the date of this press launch and, besides to the extent required by relevant regulation, we assume no obligation to replace or revise any forward-looking statements, whether or not as of the next new data, occasions and developments or different.

Jean Moten
Investor Relations
Envista Holding Firm
200, boul. S. Kraemer, constructing E
Brea, California 92821
Phone: (714) 817-7000
Fax: (714) 817-5450

SOURCE Envista Holdings Company

Associated hyperlinks


About Edith J.

Check Also

Havells India Ltd – T2FY22 outcomes replace – YES Securities

Strong progress regardless of inflationary pressures, a key asset, margins stay unfavorable Our viewpoint Havells …